What Omicron is teaching us; Teva held liable in opioid crisis

STAT looks beyond climbing case counts to outline what Omicron is already teaching us as this phase of the pandemic plays out. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

This newsletter will return in your inbox on Monday. Beyond case counts: What Omicron is teaching us By Andrew Joseph and Helen Branswell Amy Beth Bennett/South Florida Sun-Sentinel via AP With cases of the Covid-19 variant expected to surge over coming weeks, here's what we've learned so far about this phase of the pandemic. Read More New York jury holds Teva Pharmaceuticals liable in opioid crisis By Associated Press Dan Balilty/AP A jury held Teva responsible for contributing to the opioid crisis, delivering a verdict in a sweeping lawsuit filed by New York state. Read More Opinion: STAT+: Building a better on-ramp for health innovation By Laurent Levy Alex Hogan/STAT, ADOBE The process exists to help more great innovations reach their potential. Now it's time to build the system to support it. Read More Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis ⁠— at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. We wish we'd written that: STAT staffers share their favorite stories of 2021 By STAT Staff Michael Ciaglo/Getty Images All through 2021, journalists around the globe writing on Covid-19 and other pressing issues have captivated and inspired our staff at STAT. Read More Thursday, December 30, 2021       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2021, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser

Neuro firm’s ALS drug gets FDA date; IPO might come first

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES FDA sets decision date for Amylyx Pharma ALS drug that improves neuron survival The FDA has accepted Amylyx Pharmaceuticals' submission for amyotrophic lateral sclerosis drug AMX0035 and it expects to issue a regulatory decision by late June. A lot will happen before then. Amylyx recently filed for an IPO and the company's drug is slated for an advisory committee meeting ahead of an FDA decision. Sponsored Content Which cloud is the best match for your healthcare transformation priorities? From Innovaccer and MedCity News The health cloud is essential to supporting healthcare's ever expanding needs for storing, sharing and analyzing data — the lifeblood of the healthcare industry. Organizations can use it to transform patient experiences, to support analytics that would be too costly for conventional technology platforms. This report highlights how healthcare organizations can use the cloud to scale up or down, data management options, and key questions that should be asked of health cloud vendors and  enterprises so that reasonable expectations are mapped out to ensure the best match. INVEST 2022 in Chicago: Apply to Pitch Perfect Contest INVEST 2022 is going to be held March 28-30 in at the Ritz Carlton hotel in Chicago. This year, we have four new categories reflecting the pandemic-reality and how it has reshaped healthcare. Apply now for a chance to pitch LIVE in front of VC judges. Please note that companies that have pitched in the last 12 months at a MedCity event are ineligible to apply. Selected finalists will be asked to register for the conference at a reduced rate.  Cell therapy, AI drug discovery highlight 2021's record year in biotech IPOs By Frank Vinluan Wednesday, December 29, 2021 4:58 PM The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022. Read more » When it comes to breast cancer, the right data & outreach strategy impacts lives By Mike Linnert and Ryan Younger Wednesday, December 29, 2021 2:00 PM As health systems play catch up with backlogged – and potentially life-saving – screenings, it's important they prioritize people at higher risk, to ensure they have access to the preventive care they need. Read more » Delivering accessible vaccine and Covid-19 resources for children and families By Sandhya Gardner Wednesday, December 29, 2021 8:15 AM As new information around vaccines and children continues to evolve and surface,  maintaining a single point of entry for this information, that is updated in a timely fashion, can be incredibly helpful to caregivers. Read more » Free SOP Templates You Can Use Today From MedCity News Getting your Quality Management System (QMS) organized and off the ground can be time-consuming. Our team of quality experts have built a few commonly used Standard Operating Procedure (SOP) templates to help you hit the ground running. Gain access to these exclusive templates now! MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails

Looking to 2022: The digital therapeutics sector and 3 biotech trends to watch

More real-world data, getting health plans to pay and improving patient experiences could boost adoption of digital therapeutics in 2022. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Three missing pieces the digital therapeutics sector needs to succeed in 2022 By Mario Aguilar Alex Hogan/STAT, ADOBE For digital therapeutics companies, achieving widespread adoption isn't as simple as proving your products work. Read More STAT+: 3 biotech trends to watch in 2022 By Kate Sheridan Hyacinth Empinado/STAT STAT looks at 3 forces that shaped the financial landscape for biotech companies in 2021 — and why they will drive the markets in 2022. Read More 3 big questions about the Biden administration's Covid response in 2022 By Lev Facher Hyacinth Empinado/STAT STAT looked at Biden's Covid strategy and whether 2022 could finally be the year the pandemic fades into the background. Read More Sponsor content by STAT+ Biopharma breakthroughs, business, and policy analysis ⁠— at your fingertips Enjoy daily, market-moving analysis of the biotech, pharma, and life sciences industries with STAT Plus. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Don't be the last to know. Subscribe today to start reading. Opinion: Deaths of despair: the unrecognized tragedy of working class immiseration By David Introcaso ADOBE Given the well-documented correlation between income and health, HHS's lack of response to deaths of despair is beyond understanding. Read More Wednesday, December 29, 2021       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2021, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser